To fully leverage the benefits of BT-RADS, comprehensive patient clinical information is essential. Additionally, widespread adoption of BT-RADS among all MDT members involved in primary brain tumor follow-up is crucial. Even if the final BT-RADS category isn't explicitly stated, the system serves as a valuable tool for interpreting imaging studies of patients undergoing brain tumor surveillance, warranting its familiarity among healthcare professionals.

Preliminary studies suggest that BT-RADS offers several benefits for the surveillance of adult-type diffuse gliomas after treatment. These include its potential to predict mortality, its ability to guide treatment decisions by the MDT, its high inter-observer reliability among radiologists of varying experience, and its positive impact on radiology report quality. However, further refinement is needed, particularly in identifying tumor recurrence in intermediate category 3. Incorporating advanced techniques like DWI and PWI may help to better classify patients in this category, reducing unnecessary therapies due to false positive findings.